Search results for: 'deals+captor+since+2025'

Gene Editing Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Viral Vector Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Cell Therapy Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Cancer Monoclonal Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Precision Medicine in Oncology Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Artificial Intelligence (AI) Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2025

Distribution Deals in Diagnostics | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2016 to 2026

Distribution Deals in Medical Devices | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2016 to 2026

The Leading Partnering Intelligence Platform for Pharma, Biotech and Diagnostic Dealmakers

Specialty Pharmaceutical Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter specialty pharmaceutical partnering deals.